-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Yousif Capital Management LLC Sells 29 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Yousif Capital Management LLC Sells 29 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Yousif Capital Management LLC decreased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 1.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,769 shares of the medical research company's stock after selling 29 shares during the period. Yousif Capital Management LLC's holdings in Bio-Rad Laboratories were worth $1,155,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. SeaCrest Wealth Management LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter worth $26,000. Private Trust Co. NA grew its position in Bio-Rad Laboratories by 230.0% in the third quarter. Private Trust Co. NA now owns 66 shares of the medical research company's stock valued at $28,000 after purchasing an additional 46 shares in the last quarter. Atlas Capital Advisors LLC bought a new position in Bio-Rad Laboratories in the second quarter valued at $50,000. Allworth Financial LP grew its position in Bio-Rad Laboratories by 414.8% in the third quarter. Allworth Financial LP now owns 139 shares of the medical research company's stock valued at $58,000 after purchasing an additional 112 shares in the last quarter. Finally, Sentry Investment Management LLC grew its position in Bio-Rad Laboratories by 16.5% in the second quarter. Sentry Investment Management LLC now owns 148 shares of the medical research company's stock valued at $73,000 after purchasing an additional 21 shares in the last quarter. Institutional investors own 64.35% of the company's stock.
Get Bio-Rad Laboratories alerts:Bio-Rad Laboratories Stock Performance
Shares of BIO stock opened at $470.88 on Friday. The stock has a market cap of $14.04 billion, a P/E ratio of -2.33 and a beta of 0.92. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.50 and a quick ratio of 4.30. The company has a fifty day moving average price of $432.84 and a two-hundred day moving average price of $447.07. Bio-Rad Laboratories, Inc. has a one year low of $344.63 and a one year high of $670.61.
Analyst Upgrades and Downgrades
BIO has been the subject of a number of analyst reports. TheStreet downgraded shares of Bio-Rad Laboratories from a "c" rating to a "d+" rating in a research report on Thursday, October 27th. Royal Bank of Canada assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, December 6th. They issued an "outperform" rating and a $565.00 target price for the company. Credit Suisse Group cut their price target on shares of Bio-Rad Laboratories from $715.00 to $640.00 and set an "outperform" rating for the company in a research note on Friday, October 28th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, January 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $651.25.Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
See Also
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
根據Yousif Capital Management LLC最近提交給美國證券交易委員會(Securities&Exchange Commission)的Form 13F檔案,該公司在第三季度減持了Bio-Rad實驗室公司(NYSE:BioGet Rating)的股份1.0%。在此期間,該機構投資者出售了29股,持有這家醫療研究公司2,769股股票。截至最近一個季度末,Yousif Capital Management LLC持有的Bio-Rad實驗室股份價值1,155,000美元。
其他大型投資者最近也對他們在該公司的頭寸進行了調整。Seacrest Wealth Management LLC在第二季度購買了Bio-Rad實驗室價值2.6萬美元的新股。私人信託公司NA第三季度在Bio-Rad實驗室的頭寸增加了230.0%。私人信託公司NA現在擁有66股這家醫療研究公司的股票,價值28,000美元,在上個季度又購買了46股。Atlas Capital Advisors LLC在第二季度以5萬美元的價格收購了Bio-Rad實驗室的一個新頭寸。Allworth Financial LP在第三季度將其在Bio-Rad實驗室的頭寸增加了414.8%。Allworth Financial LP現在擁有139股這家醫療研究公司的股票,價值5.8萬美元,上個季度又購買了112股。最後,Sentry Investment Management LLC在第二季度將其在Bio-Rad實驗室的頭寸增加了16.5%。在上個季度又購買了21股股票後,哨兵投資管理公司現在擁有148股這家醫療研究公司的股票,價值7.3萬美元。機構投資者持有該公司64.35%的股份。
到達Bio-Rad實驗室警報:Bio-Rad實驗室股票表現
上週五,Bio股票開盤報470.88美元。該股市值為140.4億美元,本益比為-2.33,貝塔係數為0.92。該公司的債務權益比為0.14,流動比率為5.50,速動比率為4.30。該公司的50日移動平均價為432.84美元,200日移動平均價為447.07美元。Bio-Rad實驗室公司的一年低點為344.63美元,一年高位為670.61美元。
分析師升級和下調評級
BIO已經成為了許多分析師報告的主題。華爾街在10月27日星期四的一份研究報告中將Bio-Rad實驗室的股票評級從“c”下調至“d+”。加拿大皇家銀行在12月6日(星期二)的一份研究報告中承擔了對Bio-Rad實驗室股票的報道。他們對該公司的評級為“跑贏大盤”,目標價為565.00美元。瑞士信貸集團將Bio-Rad實驗室的股票目標價從715.00美元下調至640.00美元,並在10月28日星期五的一份研究報告中為該公司設定了“跑贏大盤”的評級。最後,在1月18日星期三的一份研究報告中,StockNews.com將Bio-Rad實驗室的股票評級從“買入”下調至“持有”。一名分析師對該股的評級為持有,四名分析師對該公司股票的評級為買入。根據MarketBeat,該股目前的共識評級為“適度買入”,平均目標價為651.25美元.Bio-Rad實驗室公司簡介
(獲取評級)
Bio-Rad實驗室公司致力於開發和生產用於生化、製藥和其他生命科學研究應用的特殊化學品。它通過生命科學和臨床診斷部門開展業務。生命科學部門開發、製造和銷售試劑、儀器和實驗室儀器。
另請參閱
- 免費獲取StockNews.com關於Bio-Rad實驗室的研究報告(BIO)
- 市場回顧周-1/30-2/3
- 細價股值得嗎?你應該投資細價股嗎?
- Zimmer Biomet盈利節節攀升,增長可能被計入價格
- 人工智慧軟體製造商EPAM號稱科技板塊漲幅最大
- 福特股票在盈利大幅下滑後繼續前進
想看看其他對沖基金持有哪些傳記嗎?訪問HoldingsChannel.com,獲取Bio-Rad實驗室,Inc.(紐約證券交易所:Bio-Get Rating)的最新13F檔案和內幕交易。
每天收到Bio-Rad實驗室的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bio-Rad實驗室和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧